Skip to main content

Advertisement

Table 1 Tau-reducing compounds identified from initial in-cell western screening assay

From: Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression

Functional Grouping Drug Name Tau IR as a % Of Vehicle Control GAPDH IR as a % Of Vehicle Control
Aggregation inhibitors Daunorubicin 21 ± 0 52 ± 6
  Diazaquone 66 ± 3 106 ± 6
  Methylene Blue 72 ± 6 112 ± 6
  EPICATECHIN 100 ± 4 140 ± 5
  Doxorubicin HCl 41 ± 3 56 ± 6
Antibiotics Alexidine HCl 57 ± 0 91 ± 9
  Gramicidin 58 ± 0 84 ± 0
  Ciclopirox 81 ± 2 109 ± 6
Anti-proliferatives Camptothecine 38 ± 0 71 ± 1
  Azacytidine-5 40 ± 0 56 ± 3
  Emetine diHCl 51 ± 11 69 ± 2
  Mycophenolic Acid 77 ± 0 100 ± 7
  Azaguanine-8 79 ± 0 88 ± 3
Microtubule regulators Paclitaxel 47 ± 2 61 ± 4
  Colchicine 44 ± 0 93 ± 6
  Albendazole 44 ± 4 93 ± 12
  Podophyllotoxin 37 ± 0 63 ± 2
  Nocodazole 38 ± 0 61 ± 3
  Mebendazole 45 ± 3 69 ± 4
  Fenbendazole 51 ± 2 76 ± 9
  Chelidonine 67 ± 0 96 ± 4
  Rotenone 72 ± 0 99 ± 1
Receptor Antagonists Lanotoside C 61 ± 2 79 ± 2
  Lasalocid Na salt 77 ± 2 96 ± 2
Steroids BETAMETHASONE 99 ± 0 146 ± 13
  Norethindrone 69 ± 1 110 ± 3
  1. Italics = Drugs that reduced tau levels, but that reduced GAPDH levels by >25% indicating some toxicity; SMALL CAPS = Drugs that increased GAPDH levels without reducing tau levels; Bold = Drugs resulting in >25% reductions in tau levels with <10% reductions in GAPDH levels; Bold Italics= Drugs demonstrating <25% reductions in tau levels and/or 10–25% changes in GAPDH levels. IR indicates immunoreactivity. SD indicates standard deviation. Compounds are grouped based on their functional class.